65.22
+0.81(+1.26%)
Currency In USD
| Previous Close | 64.41 |
| Open | 64.07 |
| Day High | 65.53 |
| Day Low | 63.92 |
| 52-Week High | 68.58 |
| 52-Week Low | 35.17 |
| Volume | 348,301 |
| Average Volume | 673,563 |
| Market Cap | 4.14B |
| PE | -15.03 |
| EPS | -4.34 |
| Moving Average 50 Days | 55.34 |
| Moving Average 200 Days | 53.77 |
| Change | 0.81 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $2,654.46 as of April 30, 2025 at a share price of $65.22. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,461.78 as of April 30, 2025 at a share price of $65.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Apr 07, 2025 11:00 AM GMT
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Apr 06, 2025 4:00 PM GMT
Company to host conference call on April 7 at 8 a.m. ETBOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living